After prostatectomy, PSA should fall to <0.1 ng/mL (undetectable) within 4–6 weeks. A confirmed rise to ≥0.2 ng/mL on two separate tests defines biochemical recurrence. This does not mean the cancer has spread — it means further evaluation and, in most cases, very effective treatment is needed.
What PSA is and why it matters after surgery
PSA (Prostate-Specific Antigen) is a protein produced almost exclusively by prostate cells — both normal and cancerous. After radical prostatectomy, the entire prostate is removed. In the absence of any residual prostate tissue (normal or malignant), PSA production should cease. This is why PSA becomes such a sensitive marker for disease after surgery — any detectable PSA must come from somewhere.
Before surgery, PSA reflects total prostate activity. After surgery, it reflects only potential residual or recurrent cancer. This transformation makes post-operative PSA one of the most powerful and specific oncological markers in medicine.
What "undetectable" PSA means
Modern ultrasensitive PSA assays can detect PSA down to 0.001–0.01 ng/mL. "Undetectable" typically means below the lower limit of detection of the assay used — usually <0.1 ng/mL on standard assays, or <0.01–0.03 ng/mL on ultrasensitive assays.
After prostatectomy, PSA should fall to undetectable levels within 4–6 weeks. If it has not done so by 3 months, this suggests residual prostate tissue or cancer cells — this is called a "PSA persistence" rather than a recurrence, and has different implications and treatment considerations.
PSA values can vary slightly between different laboratories and assay platforms. For meaningful longitudinal comparison, it is best to have all post-operative PSA tests done at the same laboratory. Minor fluctuations (e.g., 0.03 to 0.05 on ultrasensitive assay) are often laboratory variation rather than true rises.
PSA monitoring schedule
The following schedule is used in our practice, aligned with high-risk surveillance principles for post-prostatectomy monitoring:
Understanding your PSA values
Biochemical recurrence — what it means and what it doesn't
The term "biochemical recurrence" (BCR) sounds alarming. It simply means PSA has risen to a defined threshold — it does not mean cancer has spread, and it does not mean you are going to die of prostate cancer.
BCR occurs in approximately 20–30% of men after prostatectomy, most commonly within the first 5 years. The important context:
- BCR is not the same as clinical recurrence. Clinical recurrence means cancer has returned to a detectable anatomical location. Many men with BCR have cancer cells present but not yet visible on any imaging.
- BCR is not the same as metastatic disease. The majority of men with BCR have disease confined to the prostate bed (local recurrence) or a small number of lymph nodes — both highly treatable with curative intent.
- Time from BCR to clinical progression is often years. Studies show that the median time from BCR to evidence of metastatic disease is approximately 8 years in men with Gleason 7 disease — giving substantial time for effective intervention.
A rising PSA is a sensitive early warning system — it catches potential recurrence far earlier than any symptom would. This is a feature, not just bad news. Early PSA-detected recurrence is usually completely treatable with curative-intent salvage radiotherapy or other interventions.
PSA doubling time — the number that matters more than the level
More important than the absolute PSA level at any one point is how quickly it is rising. PSA doubling time (PSADT) — the time it takes for PSA to double — is one of the strongest predictors of whether a recurrence is likely to be local (treatable) or distant (more complex).
- PSADT >12 months: Slow rise — strongly suggests local recurrence. Salvage radiotherapy to the prostate bed is highly effective.
- PSADT 6–12 months: Moderate rise — could be local or systemic. Requires further imaging (PSMA PET-CT) to guide decision-making.
- PSADT <6 months: Rapid rise — raises concern for systemic disease. More comprehensive workup and multidisciplinary team discussion required.
Your surgeon will calculate PSADT using serial PSA values over time. This calculation requires at least 3 PSA readings to be meaningful — which is why regular monitoring from the outset is so important.
What happens if PSA rises
Imaging — PSMA PET-CT
PSMA (Prostate-Specific Membrane Antigen) PET-CT is now the standard of care for evaluating BCR after prostatectomy. It detects recurrent prostate cancer with much greater sensitivity than conventional CT or bone scan, even at PSA levels as low as 0.2–0.5 ng/mL. It can identify whether recurrence is in the prostate bed, regional lymph nodes, distant lymph nodes, or bone.
Salvage radiotherapy (SRT)
For local recurrence in the prostate bed — the most common pattern — salvage radiotherapy to the prostate bed and seminal vesicle bed is the standard treatment. When given early (PSA <0.5 ng/mL), 5-year biochemical control rates exceed 60–70%. Some men add short-course hormone therapy (ADT) to enhance the effect.
Observation (active surveillance of BCR)
For men with a very slow PSA doubling time (>12–18 months), older age, or significant comorbidities, a period of close observation without immediate intervention may be appropriate. This is always a shared decision made with your urologist and oncologist.
Hormone therapy (ADT)
For widespread or rapidly rising BCR, androgen deprivation therapy (ADT) — reducing testosterone to near-zero — slows cancer growth significantly. It is not curative but is highly effective at long-term disease control, often for many years.
Managing PSA anxiety
PSA anxiety — heightened worry in the days around each PSA test, catastrophic thinking when the value is even slightly elevated — is real, common, and under-recognised. Studies estimate that 30–40% of men undergoing PSA surveillance after cancer treatment experience clinically significant cancer-related anxiety.
Some practical approaches:
- Know your schedule. Uncertainty about when the next test is or what the result means amplifies anxiety. Ask your surgeon to walk you through the monitoring plan and what each result range means for you specifically.
- Ask what the plan is for different results. Knowing "if PSA is X, we do Y" removes the ambiguity that fuels catastrophic thinking.
- Understand that a single slightly elevated value rarely changes management. A single mildly elevated PSA almost always leads to a repeat test, not immediate treatment. The repeat is not a delay — it is the protocol.
- Talk to someone. Prostate cancer support groups (including online communities) allow you to hear from men at various stages of surveillance — many of whom have lived with stable BCR for years. This perspective is genuinely reassuring.
- Consider psychological support. Cancer-related anxiety is a recognised clinical condition and responds well to cognitive-behavioural therapy (CBT). Your oncology team can refer you.
"If my PSA rises it means the cancer has spread and I'm going to die."
BCR after prostatectomy means further evaluation is needed. Most recurrences at this early stage are localised, detectable on modern imaging, and treatable with curative intent. The median time from BCR to metastatic disease is years, not months.
"Undetectable PSA means I am cured."
An undetectable PSA is the best possible result after surgery and is highly reassuring. However, very late recurrences (beyond 10 years) can occur, particularly in higher-grade cancers. This is why annual monitoring continues indefinitely.
This article provides general educational information about PSA monitoring after prostatectomy. Your specific surveillance plan, thresholds for concern, and management of any PSA rise should be determined in consultation with your urologist and oncology team — these are individual decisions based on your cancer grade, stage, and overall health.